Factor XI Mutant Protein Bypasses Coagulation Pathways
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemorrhagic diseases, such as hemophilia, rely on frequent administration of blood coagulation factor VIII/IX preparations or costly bypass coagulation drugs like factor VIIa, which have limitations due to antibody production, short half-life, and high dosing requirements, necessitating a more effective and efficient therapeutic option.
Innovation Solution
Development of a highly active blood coagulation factor XI mutant protein and associated gene therapy/editing vector, which efficiently activates coagulation via a bypass pathway independent of factor IX/FVIII, enhancing overall coagulation function and treated through recombinant protein replacement therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If blood coagulation factor VIII/IX preparations are used to treat hemophilia, then blood coagulation factor level is improved, but antibody production occurs rendering treatment ineffective
Solution Approach 1:
The patent uses blood coagulation factor XI as an intermediary substance to activate the common coagulation pathway independently of factors VIII and IX. By introducing this alternative mediator that bypasses the problematic factors, the treatment achieves coagulation enhancement without triggering antibody production against factors VIII or IX.
2Adaptability or versatility
If bypass coagulation drugs like factor VIIa are used, then coagulation pathway bypass is achieved, but treatment cost increases and half-life decreases
Solution Approach 1:
The patent modifies the molecular structure of factor XI by introducing specific mutations (G397S, G397A, G397D, or G397E substitutions) to enhance its catalytic activity. These parameter changes in the protein structure result in significantly improved specific activity (3-5 times higher than wild type) and extended half-life, allowing for reduced dosing frequency while maintaining bypass capability.
3Adaptability or versatility
If wild-type blood coagulation factor XI is used, then bypass coagulation reaction is initiated, but catalytic efficiency is very low
Solution Approach 1:
The patent applies site-directed mutagenesis to modify the active site of factor XI, specifically substituting glycine at position 397 with serine, alanine, aspartic acid, or glutamic acid. These parameter changes in amino acid composition dramatically enhance the catalytic efficiency toward bypass substrates (FX, FV, TFPI) while preserving the ability to initiate bypass coagulation reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The highly active factor XI mutant protein significantly improves blood coagulation activity, effectively treating hemorrhagic diseases by bypassing traditional coagulation pathways, offering promising prospects for gene therapy and recombinant protein replacement.
Implementation Method 1
The blood coagulation activity of the blood coagulation factor XI is mainly associated with its ability to efficiently cleave and activate blood coagulation factor IX. However, other components in the coagulation reaction may also be catalytically cleaved by the blood coagulation factor XI.
Data Source
AI summary
Methods of preparing and using a highly active blood coagulation factor XI mutant and a gene therapy/editing vector thereof and a recombinant/fusion protein thereof. The nucleotide sequence of the mutant is as shown in SEQ ID NOs: 1-6, and the amino acid sequence is as shown in SEQ ID NO: 7.